Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]

BIOLOGICAL2 trials

Sponsors

Baxalta now part of Shire

Conditions

Congenital Factor VIII (FVIII) DeficiencyHemophilia A

Phase 4

Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

CompletedNCT00916032

Baxalta now part of ShireHemophilia A

Start: 2009-06-29End: 2010-04-01Updated: 2021-05-19

Unknown Phase

ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)

CompletedNCT02093741

Baxalta now part of ShireCongenital Factor VIII (FVIII) Deficiency, Hemophilia A

Start: 2013-09-20End: 2016-01-20Updated: 2021-03-17

Related Papers

Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A

Haemophilia2020-04-27